Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Medtronic
AstraZeneca
McKesson
Moodys

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

Litigation Details for Allergan Inc. v. Alcon Inc. (D. Del. 2004)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Allergan Inc. v. Alcon Inc. (D. Del. 2004)

Docket   Start Trial Date Filed 2004-08-24
Court District Court, D. Delaware Date Terminated 2006-03-07
Cause 28:1338 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand Plaintiff Referred To
Parties ALCON INC.; ALCON LABORATORIES, INCORPORATED; ALCON RESEARCH LTD.; ALLERGAN INC.; ALLERGAN SALES LLC
Patents 5,736,165; 5,922,695; 5,977,089; 6,043,230; 6,153,592; 6,204,257; 6,248,741; 6,562,873; 6,627,210; 6,641,843; 6,673,337
Attorneys Glenn Christopher Mandalas; Josy W. Ingersoll; Karen Elizabeth Keller; Melanie K. Sharp; Sean Paul Hayes; William J. Marsden , Jr.
Firms Baird Mandalas LLC; Shaw Keller LLP; Young, Conaway, Stargatt & Taylor LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Allergan Inc. v. Alcon Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in Allergan Inc. v. Alcon Inc.
The biologic drug covered by the patents cited in this case is   Start Trial .

Details for Allergan Inc. v. Alcon Inc. (D. Del. 2004)

Date Filed Document No. Description Snippet Link To Document
2005-08-09 115 Answering Brief in Opposition might stick. With regard to U.S. Patent No. 6,627,210 (which is not even in suit), Alcon accuses…contends that both of the patents-in-suit in this case, as well as a parent patent, are products of a vast… inventors of the patents-in-suit, and one of the attorneys prosecuting the patents-in-suit to “defraud…non-infringement of the ’ 337 patent and one on lack of written description of the ’ 874 patent. These motions were…on the ’ 834 patent.” (D.I. 107, at 3.) That is akin to Allergan asserting a new patent against Alcon External link to document
2006-01-16 157 Exhibit Redacted Ex. 5 pt. 1 J olin R. Crison and Gordor; L. Amidon. US #6,153,592, Issued Nov. 28, 2000, Enhancing the Bioavailability…$183,196 (DC Yr l): 2005-2010; G.L. Arnidon (Co-PI). PATENTS US #6,669,954, Issued Dec 30, 2003. Controlled…Document 157-3 Filed 01/16/2006 Page 7 of 25 U.S. Patent #5,455,286, Issued October 1995; Bioactive Composition…Gordon L. Arnidon and Jennifer B. Dressman. U.S. Patent #4,685,918, Issued August 11, 1987; Lipid Osrnotic…2004 7 March 2006 1:04-cv-00968 830 Patent Plaintiff District Court, D. External link to document
2006-01-24 167 Supplement part 2 904,018 filed Jul. 10, 2001, now U.S. Pat. No. 6,627,210; which elaimsbenent of 60/218.200 filed Jul. 14…VERSION - PUBLICLY FILED U.S. Patent Nn. 6,673,337 Claim U.S. Patent No. 5,091,528 (Gluchowski) …VERSION ~ PUBLICLY FILED U.S. Patent No. 6,673,337 Claim U.S. Patent No. 5,091,528 (Gluchowski) …VERSION ~ PUBLICLY FILED U.S. Patent No. 6,673,337 Claim U.S. Patent No. 5,212,196 (House) l. …VERSION - PUBLICLY FILED U.S. Patent No. 6,673,337 Claim U.S. Patent No. 5,776,445 (Cohen) l External link to document
2006-01-24 168 Exhibit Tab 12 aspect of Alphagan® P; United States Patent Nos.; 5,424,073; 6,562,873; and 6,627,210. Allergan did not sue…of the ’334 patent, Alcon infringes the asserted claims of the ’834 patent 2. ’337 Patent 76. The Court…by the applicant for patent or (2) a patent granted on an application for patent by another filed in the…two United Slales Palen§s. The patents-in-sui£ are Uni£ed States Patent Nos. 6,641,834 (“the ’334 patcnt…adrenergic agonists. [’334 patent, Coi. lo, l. 45 to Col. lS, l. 22, and `337 patent, Coi_ 16, i. 41 to Col External link to document
2006-02-02 179 Exhibit part 1 A-D _lw£ 41. The patents most relevant to this suit include: a. U.S. Patent No. 6,627,210 (hereinafter “…United States Patents Nos. 6,641,834 (“the '834 patent”) and 6,673,337 (“the '337 patent”). rae_a…United States Patent Nos. 6,641,834 (the “’834 patent”) and 6,673,337 (the “’337 patent”) invalid, not…lt;e (U.S. Patent No. 5,215,991) in view ofBeck et al. (U.S. Patent No. 6358935). The Patent Examiner noted…_¢i 7. Alcon admits that the ’834 patent reflects that such patent, entitled “Cornpositions Containing External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Harvard Business School
Boehringer Ingelheim
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.